Nobelpharma 
Welcome,         Profile    Billing    Logout  
 7 Products   0 Diseases  7 Products   10 Trials   152 News 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Molbreevi (molgramostim) / Savara, Nobelpharma
2020-001263-85: A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation.

Ongoing
3
160
Europe
Molgramostim 300 µg nebulizer solution, [na], Nebulisation solution
Savara ApS, SAVARA APS, Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis (aPAP), Pulmonary Alveolar Proteinosis, commonly known by the acronym PAP, is a rare lung disease characterized by the build-up of proteinaceous material in the alveoli (air sacs) of the lungs., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
160
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
11/24
NCT06431776: Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Not yet recruiting
3
5
US
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF).
Savara Inc.
Autoimmune Pulmonary Alveolar Proteinosis
01/27
08/27
2017-003374-14: A pilot clinical trial of inhaled molgramostim in patients with antibiotic-resistant bacterial infection.

Not yet recruiting
2
30
Europe
Molgramostim nebuliser solution (Molgradex), Nebuliser solution
Savara ApS, Savara ApS
Treatment-resistant pulmonary non-tuberculosis mycobacterial (NTM) infection, Lung infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2020-001654-21: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia Granulozyten-Monozyten-Kolonie-stimulierende Faktor (GM-CSF) Inhalation zur Verhinderung des akuten Lungenversagens bei COVID-19-Pneumonie

Not yet recruiting
2
238
Europe
Molgradex 300 mcg nebuliser solution, Nebuliser solution
Justus-Liebig-University Gießen, DZL (Deutsche Zentrum für Lungenforschung)
COVID-19 pneumonia COVID-19-Pneumonie, COVID-19 pneumonia COVID-19-Pneumonie, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
GI-HOPE, NCT02595060 / 2014-002479-28: Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

Completed
2
45
Europe
inhaled molgramostim (rhGM-CSF), inhaled placebo
University of Giessen
ARDS
09/21
07/22
GI-COVID, NCT04569877: GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia

Completed
2
63
Europe
Molgramostim nebuliser solution, Placebo nebuliser solution
University of Giessen
Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19 Pneumonia
06/22
09/22
NCT04823962: Effect of rhGM-CSF on the Healing of Venous Leg Ulcers

Active, not recruiting
2
6
Europe
rhGM-CSF + hydrogel, Repogel, Molgramostim, Placebo hydrogel, Standard care
Reponex Pharmaceuticals A/S
Venous Leg Ulcer
12/23
12/23
NCT05501340: PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Not yet recruiting
1/2
40
NA
Serplulimab, HLX10, Molgramostim, rhGM-CSF, Hypofractionated radiotherapy/Sterotactic body radiotherapy
Second Affiliated Hospital of Soochow University
Malignant Ascites
12/22
09/24
NCT06546098: Molgramostim Nebulizer Solution Expanded Access Program Protocol

Available
N/A
NA
Molgramostim nebulizer solution, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)
Savara Inc.
Autoimmune Pulmonary Alveolar Proteinosis
 
 
Danyelza (naxitamab-gqgk) / Y-mAbs Therap
NCT06047535: Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Not yet recruiting
4
62
NA
Naxitamab, GM-CSF, isotretinoin
SciClone Pharmaceuticals
Neuroblastoma
06/27
08/27
NICE, NCT06438614: A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

Completed
2
47
Europe
HITS, Naxitamab + GM-CSF cycles, NICE
Fundació Sant Joan de Déu
Refractory Neuroblastoma, Soft Tissue Cancer
07/23
10/23
2022-003812-98: To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma. Ocena skuteczności i bezpieczeństwa zastosowania naksytamabu u pacjentów z opornym na leczenie mięsakiem Ewinga.

Not yet recruiting
2
24
Europe
Concentrate for solution for infusion, DANYELZA
Institute of Mother and Child, Medical Research Agency
Ewing's sarcoma, Ewing's sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT03033303: A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Active, not recruiting
2
59
US
Hu3F8, GM-CSF, Isotretinoin
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma
06/26
06/26
NCT06528496: N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Recruiting
2
45
US
DANYELZA, Naxitamab, Sargramostim, granulocyte-macrophage colony-stimulating factor, GM-CSF, Cytoxan, Cyclophosphamide, Topotecan, Vincristine, Oncovin, Doxorubicin, Adriamycin, Ifosfamide, Isophosphamide, Etoposide, VePesid, Etopophos, VP-16, Carboplatin, Paraplatin, Irinotecan, Camptosar, Temozolomide, Temodar
Memorial Sloan Kettering Cancer Center
High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
07/29
07/29
NCT06540963: Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Recruiting
2
98
US
Tipifarnib, R115777, Naxitamab, Danyelza
Giselle Sholler
Neuroblastoma Recurrent
12/30
12/35
NCT05754684: Quadruple Immunotherapy for Neuroblastoma

Recruiting
2
29
RoW
Natural killer cell, NK cell, Dinutuximab beta, Ch14.18, Interleukin-2, Aldesleukin, Granulocyte-Macrophage Colony-Stimulating Factor, Sargramostim, Spironolactone, Aldactone, Naxitamab, hu3F8
Hong Kong Children's Hospital, The University of Hong Kong
Neuroblastoma Recurrent
12/24
12/25
NCT06013618: Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Recruiting
2
120
RoW
Naxitamab monotherapy, hu3F8, GM-CSF, Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor, Irinotecan, DNA topoisomerase I inhibitor, Temozolomide, Temozolomide for Injection, Naxitamab in combination therapy, GM-CSF with combination regimen, Sintilimab, PD-1 antibody
Sun Yat-sen University, Hainan General Hospital
Neuroblastoma
12/26
12/27
Study 201, NCT03363373 / 2004-000280-99: Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow

Recruiting
2
122
Europe, Canada, US, RoW
GM-CSF + Naxitamab
Y-mAbs Therapeutics
Neuroblastoma
04/26
04/28
NCT02502786: Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Active, not recruiting
2
46
US
humanized anti-GD2 antibody, hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Children's Hospital Los Angeles, M.D. Anderson Cancer Center, Y-mAbs Therapeutics
Recurrent Osteosarcoma
07/25
07/25
NCT05489887: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting
2
76
Canada, US
Naxitamab, Danyelza, Ceritinib
Giselle Sholler, Y-mAbs
High-risk Neuroblastoma
09/26
09/33
NCT05968768: To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Recruiting
2
24
Europe
Naxitamab, danyelza
Anna Raciborska, Wroclaw Medical University
Ewing Sarcoma
05/27
07/28
Study 12-230, NCT01757626: Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Active, not recruiting
1/2
186
US
Hu3F8 With GM-CSF
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma
12/25
12/25
NCT06026657: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Recruiting
1/2
42
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Naxitamab, Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized, Danyelza, Hu3F8, Humanized Anti-GD2 Antibody 3F8, Humanized Monoclonal Antibody Hu3f8-IGG1, Universal Donor Expanded TGF-beta-imprinted NK Cells, Allogeneic TGFBi Expanded NK Cells, UD TGF-betai NK Cells, Universal Donor TGF-beta Imprinted Expanded NK Cells
Margaret Gatti-Mays
Anatomic Stage IV Breast Cancer AJCC V8, HER2-Negative Breast Carcinoma
12/26
12/26
NCT07011654: Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Not yet recruiting
1/2
31
US
Sacituzumab govitecan, Naxitamab
M.D. Anderson Cancer Center, Y-mAbs Therapeutics
Metastatic Triple-Negative Breast Cancer
07/28
11/30
NCT01419834: Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Completed
1
68
US
Humanized 3F8 Monoclonal Antibody (Hu3F8)
Memorial Sloan Kettering Cancer Center, Band of Parents, Y-mAbs Therapeutics
Neuroblastoma
08/23
08/23
NCT02650648: Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Active, not recruiting
1
85
US
cyclophosphamide, Cytoxan®, NK cells, hu3F8, rIL-2
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma, High-Risk
01/26
01/26
NCT03189706: Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Active, not recruiting
1
48
US
Irinotecan, temozolomide, Hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma (NB)
06/26
06/26
NCT07027748: Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Recruiting
1
18
US
Naxitamab, Irinotecan, Temozolomide, Temodal, Temodar, Sargramostim granulocyte-macrophage colony stimulating factor, Leukine
Steven DuBois, MD, Y-mAbs Therapeutics
Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma
12/26
12/27
NCT04501757: Naxitamab and GM-CSF in People With Neuroblastoma

No Longer Available
N/A
US
Naxitamab/GM-CSF
Memorial Sloan Kettering Cancer Center
High-Risk Neuroblastoma
 
 
NCT02307630: PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Active, not recruiting
N/A
7
US
124I-Humanized 3F8
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Melanoma, Neuroblastoma, Sarcoma
11/25
11/25
NCT06574698: Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Recruiting
N/A
64
RoW
Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Guangzhou Women and Children's Medical Center
Neuroblastoma, GD2 Antibody (Naxitamab)
12/29
12/32
arbekacin (NPC-14) / Nobelpharma
NCT01659515: Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

No Longer Available
N/A
US
Arbekacin Sulfate, Arbekacin, Habekacin
U.S. Army Medical Research and Development Command, Meiji Seika Pharma Co., Ltd., Uniformed Services University of the Health Sciences
Infection Due to Resistant Organism
 
 
NPC-21 / Nobelpharma, Evec
NCT04225923: A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

Completed
2
87
Japan, US
NPC-21 Low dose, NPC-21 High dose, NPC-21 Placebo
Nobelpharma
Cytomegalovirus Disease
11/22
02/23
Rapalimus Gel (sirolimus gel) / Nobelpharma
NCT05495425: Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC

Completed
3
43
Japan
NPC-12Y gel, NPC-12Y placebo gel
Nobelpharma
Tuberous Sclerosis Complex
10/24
10/24
Melatobel (melatonin) / Nobelpharma
No trials found
NPC-27 / Nobelpharma, Middle East Technical University, Bilkent University, Tokyo Metropolitan Institute of Medical Science
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Molbreevi (molgramostim) / Savara, Nobelpharma
2020-001263-85: A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation.

Ongoing
3
160
Europe
Molgramostim 300 µg nebulizer solution, [na], Nebulisation solution
Savara ApS, SAVARA APS, Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis (aPAP), Pulmonary Alveolar Proteinosis, commonly known by the acronym PAP, is a rare lung disease characterized by the build-up of proteinaceous material in the alveoli (air sacs) of the lungs., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
160
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
11/24
NCT06431776: Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Not yet recruiting
3
5
US
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF).
Savara Inc.
Autoimmune Pulmonary Alveolar Proteinosis
01/27
08/27
2017-003374-14: A pilot clinical trial of inhaled molgramostim in patients with antibiotic-resistant bacterial infection.

Not yet recruiting
2
30
Europe
Molgramostim nebuliser solution (Molgradex), Nebuliser solution
Savara ApS, Savara ApS
Treatment-resistant pulmonary non-tuberculosis mycobacterial (NTM) infection, Lung infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2020-001654-21: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia Granulozyten-Monozyten-Kolonie-stimulierende Faktor (GM-CSF) Inhalation zur Verhinderung des akuten Lungenversagens bei COVID-19-Pneumonie

Not yet recruiting
2
238
Europe
Molgradex 300 mcg nebuliser solution, Nebuliser solution
Justus-Liebig-University Gießen, DZL (Deutsche Zentrum für Lungenforschung)
COVID-19 pneumonia COVID-19-Pneumonie, COVID-19 pneumonia COVID-19-Pneumonie, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
GI-HOPE, NCT02595060 / 2014-002479-28: Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

Completed
2
45
Europe
inhaled molgramostim (rhGM-CSF), inhaled placebo
University of Giessen
ARDS
09/21
07/22
GI-COVID, NCT04569877: GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia

Completed
2
63
Europe
Molgramostim nebuliser solution, Placebo nebuliser solution
University of Giessen
Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19 Pneumonia
06/22
09/22
NCT04823962: Effect of rhGM-CSF on the Healing of Venous Leg Ulcers

Active, not recruiting
2
6
Europe
rhGM-CSF + hydrogel, Repogel, Molgramostim, Placebo hydrogel, Standard care
Reponex Pharmaceuticals A/S
Venous Leg Ulcer
12/23
12/23
NCT05501340: PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Not yet recruiting
1/2
40
NA
Serplulimab, HLX10, Molgramostim, rhGM-CSF, Hypofractionated radiotherapy/Sterotactic body radiotherapy
Second Affiliated Hospital of Soochow University
Malignant Ascites
12/22
09/24
NCT06546098: Molgramostim Nebulizer Solution Expanded Access Program Protocol

Available
N/A
NA
Molgramostim nebulizer solution, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF)
Savara Inc.
Autoimmune Pulmonary Alveolar Proteinosis
 
 
Danyelza (naxitamab-gqgk) / Y-mAbs Therap
NCT06047535: Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Not yet recruiting
4
62
NA
Naxitamab, GM-CSF, isotretinoin
SciClone Pharmaceuticals
Neuroblastoma
06/27
08/27
NICE, NCT06438614: A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

Completed
2
47
Europe
HITS, Naxitamab + GM-CSF cycles, NICE
Fundació Sant Joan de Déu
Refractory Neuroblastoma, Soft Tissue Cancer
07/23
10/23
2022-003812-98: To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma. Ocena skuteczności i bezpieczeństwa zastosowania naksytamabu u pacjentów z opornym na leczenie mięsakiem Ewinga.

Not yet recruiting
2
24
Europe
Concentrate for solution for infusion, DANYELZA
Institute of Mother and Child, Medical Research Agency
Ewing's sarcoma, Ewing's sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT03033303: A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Active, not recruiting
2
59
US
Hu3F8, GM-CSF, Isotretinoin
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma
06/26
06/26
NCT06528496: N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Recruiting
2
45
US
DANYELZA, Naxitamab, Sargramostim, granulocyte-macrophage colony-stimulating factor, GM-CSF, Cytoxan, Cyclophosphamide, Topotecan, Vincristine, Oncovin, Doxorubicin, Adriamycin, Ifosfamide, Isophosphamide, Etoposide, VePesid, Etopophos, VP-16, Carboplatin, Paraplatin, Irinotecan, Camptosar, Temozolomide, Temodar
Memorial Sloan Kettering Cancer Center
High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
07/29
07/29
NCT06540963: Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Recruiting
2
98
US
Tipifarnib, R115777, Naxitamab, Danyelza
Giselle Sholler
Neuroblastoma Recurrent
12/30
12/35
NCT05754684: Quadruple Immunotherapy for Neuroblastoma

Recruiting
2
29
RoW
Natural killer cell, NK cell, Dinutuximab beta, Ch14.18, Interleukin-2, Aldesleukin, Granulocyte-Macrophage Colony-Stimulating Factor, Sargramostim, Spironolactone, Aldactone, Naxitamab, hu3F8
Hong Kong Children's Hospital, The University of Hong Kong
Neuroblastoma Recurrent
12/24
12/25
NCT06013618: Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Recruiting
2
120
RoW
Naxitamab monotherapy, hu3F8, GM-CSF, Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor, Irinotecan, DNA topoisomerase I inhibitor, Temozolomide, Temozolomide for Injection, Naxitamab in combination therapy, GM-CSF with combination regimen, Sintilimab, PD-1 antibody
Sun Yat-sen University, Hainan General Hospital
Neuroblastoma
12/26
12/27
Study 201, NCT03363373 / 2004-000280-99: Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow

Recruiting
2
122
Europe, Canada, US, RoW
GM-CSF + Naxitamab
Y-mAbs Therapeutics
Neuroblastoma
04/26
04/28
NCT02502786: Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Active, not recruiting
2
46
US
humanized anti-GD2 antibody, hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Children's Hospital Los Angeles, M.D. Anderson Cancer Center, Y-mAbs Therapeutics
Recurrent Osteosarcoma
07/25
07/25
NCT05489887: Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Recruiting
2
76
Canada, US
Naxitamab, Danyelza, Ceritinib
Giselle Sholler, Y-mAbs
High-risk Neuroblastoma
09/26
09/33
NCT05968768: To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Recruiting
2
24
Europe
Naxitamab, danyelza
Anna Raciborska, Wroclaw Medical University
Ewing Sarcoma
05/27
07/28
Study 12-230, NCT01757626: Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Active, not recruiting
1/2
186
US
Hu3F8 With GM-CSF
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma
12/25
12/25
NCT06026657: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Recruiting
1/2
42
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Naxitamab, Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized, Danyelza, Hu3F8, Humanized Anti-GD2 Antibody 3F8, Humanized Monoclonal Antibody Hu3f8-IGG1, Universal Donor Expanded TGF-beta-imprinted NK Cells, Allogeneic TGFBi Expanded NK Cells, UD TGF-betai NK Cells, Universal Donor TGF-beta Imprinted Expanded NK Cells
Margaret Gatti-Mays
Anatomic Stage IV Breast Cancer AJCC V8, HER2-Negative Breast Carcinoma
12/26
12/26
NCT07011654: Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Not yet recruiting
1/2
31
US
Sacituzumab govitecan, Naxitamab
M.D. Anderson Cancer Center, Y-mAbs Therapeutics
Metastatic Triple-Negative Breast Cancer
07/28
11/30
NCT01419834: Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Completed
1
68
US
Humanized 3F8 Monoclonal Antibody (Hu3F8)
Memorial Sloan Kettering Cancer Center, Band of Parents, Y-mAbs Therapeutics
Neuroblastoma
08/23
08/23
NCT02650648: Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Active, not recruiting
1
85
US
cyclophosphamide, Cytoxan®, NK cells, hu3F8, rIL-2
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma, High-Risk
01/26
01/26
NCT03189706: Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Active, not recruiting
1
48
US
Irinotecan, temozolomide, Hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma (NB)
06/26
06/26
NCT07027748: Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Recruiting
1
18
US
Naxitamab, Irinotecan, Temozolomide, Temodal, Temodar, Sargramostim granulocyte-macrophage colony stimulating factor, Leukine
Steven DuBois, MD, Y-mAbs Therapeutics
Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma
12/26
12/27
NCT04501757: Naxitamab and GM-CSF in People With Neuroblastoma

No Longer Available
N/A
US
Naxitamab/GM-CSF
Memorial Sloan Kettering Cancer Center
High-Risk Neuroblastoma
 
 
NCT02307630: PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Active, not recruiting
N/A
7
US
124I-Humanized 3F8
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Melanoma, Neuroblastoma, Sarcoma
11/25
11/25
NCT06574698: Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Recruiting
N/A
64
RoW
Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
Guangzhou Women and Children's Medical Center
Neuroblastoma, GD2 Antibody (Naxitamab)
12/29
12/32
arbekacin (NPC-14) / Nobelpharma
NCT01659515: Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

No Longer Available
N/A
US
Arbekacin Sulfate, Arbekacin, Habekacin
U.S. Army Medical Research and Development Command, Meiji Seika Pharma Co., Ltd., Uniformed Services University of the Health Sciences
Infection Due to Resistant Organism
 
 
NPC-21 / Nobelpharma, Evec
NCT04225923: A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

Completed
2
87
Japan, US
NPC-21 Low dose, NPC-21 High dose, NPC-21 Placebo
Nobelpharma
Cytomegalovirus Disease
11/22
02/23
Rapalimus Gel (sirolimus gel) / Nobelpharma
NCT05495425: Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC

Completed
3
43
Japan
NPC-12Y gel, NPC-12Y placebo gel
Nobelpharma
Tuberous Sclerosis Complex
10/24
10/24
Melatobel (melatonin) / Nobelpharma
No trials found
NPC-27 / Nobelpharma, Middle East Technical University, Bilkent University, Tokyo Metropolitan Institute of Medical Science
No trials found

Download Options